Research programme: CAR-T cell therapeutics - Regen BioPharma
Alternative Names: DuraCAR-T therapy - Regen Biopharma; NR2F6 CAR-T therapy - Regen BiopharmaLatest Information Update: 27 Oct 2023
At a glance
- Originator Regen BioPharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Oct 2023 Regen Biopharma files a patent application for designing T cells which can tamp down on the uncontrolled immune activation in multiple autoimmune disorders
- 25 Oct 2023 Pharmacodynamics data from a preclinical trial in solid tumours released by Regen BioPharma
- 10 Oct 2023 Pharmacodynamics data from a preclinical trial in solid tumours released by Regen BioPharma